$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-K Financial Statement

#000114420415059224 Filed on October 13, 2015

Income Statement

Concept	2015 Q2	2014 Q2	2014
Revenue	$320.0K	$210.0K	$205.0K
YoY Change	52.38%	-66.13%	-79.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.450M	$1.950M	$3.840M
YoY Change	-25.64%	105.26%	-1.79%
% of Gross Profit
Research & Development	$760.0K	-$590.0K	$1.898M
YoY Change	-228.81%	-160.82%	-44.68%
% of Gross Profit
Depreciation & Amortization	$100.0K	$90.00K	$3.000K
YoY Change	11.11%	0.0%	50.0%
% of Gross Profit
Operating Expenses	$2.210M	$1.360M	$4.045M
YoY Change	62.5%	-29.17%	-47.29%
Operating Profit			-$3.840M
YoY Change			-42.4%
Interest Expense	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$10.00K	$10.00K	$174.0K
YoY Change	0.0%	0.0%	-62.9%
Pretax Income	-$1.890M	-$1.140M	-$3.670M
YoY Change	65.79%	-13.64%	-40.81%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.890M	-$1.140M	-$3.666M
YoY Change	65.79%	-13.64%	-40.85%
Net Earnings / Revenue	-590.63%	-542.86%	-1788.29%
Basic Earnings Per Share
Diluted Earnings Per Share	-$248.0K	-$173.8K	-$582.5K
COMMON SHARES
Basic Shares Outstanding	76.76M shares	65.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2014 Q2	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.490M	$3.590M	$3.590M
YoY Change	164.35%	-18.59%	-18.59%
Cash & Equivalents	$9.494M	$3.590M
Short-Term Investments
Other Short-Term Assets	$17.00K	$8.000K	$120.0K
YoY Change	112.5%	-74.19%	-90.08%
Inventory
Prepaid Expenses
Receivables	$445.0K	$205.0K	$210.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.12M	$3.913M	$3.910M
YoY Change	158.65%	-41.02%	-41.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.00K	$6.000K	$10.00K
YoY Change	116.67%	0.0%	0.0%
Goodwill
YoY Change
Intangibles	$2.360M	$2.575M
YoY Change	-8.35%	-5.09%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.373M	$2.581M	$2.580M
YoY Change	-8.06%	-5.08%	-4.8%
TOTAL ASSETS
Total Short-Term Assets	$10.12M	$3.913M	$3.910M
Total Long-Term Assets	$2.373M	$2.581M	$2.580M
Total Assets	$12.49M	$6.494M	$6.490M
YoY Change	92.39%	-30.58%	-30.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.104M	$297.0K	$300.0K
YoY Change	271.72%	-87.63%	-87.5%
Accrued Expenses	$159.0K	$98.00K	$100.0K
YoY Change	62.24%	-94.8%	-94.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.263M	$395.0K	$400.0K
YoY Change	219.75%	-90.78%	-90.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.263M	$395.0K	$400.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.263M	$395.0K	$400.0K
YoY Change	219.75%	-90.79%	-90.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.83M	-$41.20M
YoY Change	16.08%	9.77%
Common Stock	$59.08M	$47.30M
YoY Change	24.91%	11.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.23M	$6.099M	$6.100M
YoY Change
Total Liabilities & Shareholders Equity	$12.49M	$6.494M	$6.490M
YoY Change	92.39%	-30.58%	-30.59%

Cashflow Statement

Concept	2015 Q2	2014 Q2	2014
OPERATING ACTIVITIES
Net Income	-$1.890M	-$1.140M	-$3.666M
YoY Change	65.79%	-13.64%	-40.85%
Depreciation, Depletion And Amortization	$100.0K	$90.00K	$3.000K
YoY Change	11.11%	0.0%	50.0%
Cash From Operating Activities	-$1.210M	-$690.0K	-$4.120M
YoY Change	75.36%	-24.18%	-15.03%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$60.00K	$4.000K
YoY Change	16.67%	50.0%	-42.86%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$70.00K	-$60.00K	-$260.0K
YoY Change	16.67%	50.0%	33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$480.0K
YoY Change			-88.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.700M	0.000	3.550M
YoY Change		-100.0%	-7.41%
NET CHANGE
Cash From Operating Activities	-1.210M	-690.0K	-4.120M
Cash From Investing Activities	-70.00K	-60.00K	-260.0K
Cash From Financing Activities	2.700M	0.000	3.550M
Net Change In Cash	1.420M	-750.0K	-830.0K
YoY Change	-289.33%	-126.04%	-31.4%
FREE CASH FLOW
Cash From Operating Activities	-$1.210M	-$690.0K	-$4.120M
Capital Expenditures	-$70.00K	-$60.00K	$4.000K
Free Cash Flow	-$1.140M	-$630.0K	-$4.124M
YoY Change	80.95%	-27.59%	-15.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q4	dei	Entity Public Float EntityPublicFloat	33200000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9494000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	445000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	182000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	10121000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2360000	USD
CY2015Q2	us-gaap	Assets Assets	12494000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	159000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1104000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	77000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59006000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	47235000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47827000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41202000	USD
CY2015	dei	Trading Symbol TradingSymbol	IBIO
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77325410	shares
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3590000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	205000	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	118000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	3913000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2575000	USD
CY2014Q2	us-gaap	Assets Assets	6494000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	297000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	1263000	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	11231000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	6099000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12494000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6494000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	1851000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3495000	USD
CY2015	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	0	USD
CY2014	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	-1041000	USD
CY2015	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	0	USD
CY2014	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	-700000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	4045000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-3840000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2015	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	0	USD
CY2014	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	-122000	USD
CY2015	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	32000	USD
CY2014	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	42000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	41000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	174000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-6625000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-3666000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6650000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3666000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71495000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62968000	shares
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2015	ibio	Common Stock Issued For Warrant Exercises Value CommonStockIssuedForWarrantExercisesValue	867000	USD
CY2015	ibio	Stock Issued During Period Value Capital Contribution And Commitment Fee StockIssuedDuringPeriodValueCapitalContributionAndCommitmentFee	1000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2015	ibio	Effect Of Settlement Agreement EffectOfSettlementAgreement	0	USD
CY2014	ibio	Effect Of Settlement Agreement EffectOfSettlementAgreement	1863000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	914000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1075000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	358000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	358000	USD
CY2015	us-gaap	Depreciation Depreciation	5000	USD
CY2014	us-gaap	Depreciation Depreciation	3000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-48000	USD
CY2014	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-56000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	240000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	205000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	806000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	73000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-28000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4725000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4116000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	202000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-215000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-259000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	480000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	867000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3100000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	29000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10867000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3551000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-23000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5904000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-824000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4414000	USD
CY2015	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	0	USD
CY2014	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	12000	USD
CY2015	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	-12000	USD
CY2014	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	20000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2360000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2575000	USD
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	15000000	shares
CY2014	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	7750000	shares
CY2014	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	8876029	shares
CY2014	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.40
CY2014	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	1.18
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	25395940	shares
CY2014	ibio	General And Administrative Effect Of Amendment To Collaboration And License Agreement GeneralAndAdministrativeEffectOfAmendmentToCollaborationAndLicenseAgreement	1007000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6760000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1990000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	266666	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8483334	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.45
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.62
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8769911	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.23
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6625000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3666000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	9500000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6600000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8500000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8800000	shares
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	914000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1075000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6700000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1740000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	700000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9523334	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9499292	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6156677	shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.88
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.75
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.22
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.42
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1836000	USD
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1105000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	153000	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	38000	USD
CY2015Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2014Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77205410	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77205410	shares
CY2014	ibio	Research And Development Effect Of Amendment To Collaboration And License Agreement ResearchAndDevelopmentEffectOfAmendmentToCollaborationAndLicenseAgreement	-1007000	USD
CY2015	ibio	General And Administrative Effect Of Amendment To Collaboration And License Agreement GeneralAndAdministrativeEffectOfAmendmentToCollaborationAndLicenseAgreement	0	USD
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65642095	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65642095	shares
CY2015	ibio	Research And Development Effect Of Amendment To Collaboration And License Agreement ResearchAndDevelopmentEffectOfAmendmentToCollaborationAndLicenseAgreement	0	USD
CY2015	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	995000	USD
CY2014	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	527000	USD
CY2015	ibio	Reversal Of Accrued Warrants ReversalOfAccruedWarrants	0	USD
CY2014	ibio	Reversal Of Accrued Warrants ReversalOfAccruedWarrants	71000	USD
CY2015	ibio	Effect Of Amendment To Collaboration And License Agreement On Accounts Receivable And Accounts Payable EffectOfAmendmentToCollaborationAndLicenseAgreementOnAccountsReceivableAndAccountsPayable	0	USD
CY2014	ibio	Effect Of Amendment To Collaboration And License Agreement On Accounts Receivable And Accounts Payable EffectOfAmendmentToCollaborationAndLicenseAgreementOnAccountsReceivableAndAccountsPayable	1007000	USD
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods, and reduced production time, capital and operating costs for biopharmaceuticals. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> one</font> business segment under the direction of its Executive Chairman. The Company has two wholly-owned subsidiaries, iBioDefense Biologics LLC (“iBioDefense”), a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology, and iBio Peptide Therapeutics LLC, a Delaware limited liability company formed in November 2013. Both of these subsidiaries are dormant. Additionally the Company has a 99% interest in a subsidiary organized in Brazil, iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”), to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/FioCruz (“FioCruz”) beyond the current Yellow Fever Vaccine program (see Note 8) and development of biosimilar products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	165000	USD
CY2014Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	110000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	17000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	8000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5281000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5168000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2921000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2593000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	353000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	337000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	319000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	289000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	256000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	806000	USD
CY2015	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2015	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	1711000	shares
CY2015	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	425587	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6633324	shares
CY2015Q2	ibio	Class Of Warrants Or Right Exercisable ClassOfWarrantsOrRightExercisable	6633324	shares
CY2015	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.51
CY2015	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0.66
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2015Q2	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable	1.63
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription	Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.43
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.40
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1100000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1200000	shares
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2299000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1267000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-377000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-215000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-12000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2015	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-2688000	USD
CY2014	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-1482000	USD
CY2015	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	2688000	USD
CY2014	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	1482000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14213000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11954000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3992000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3626000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	890000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	764000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	188000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	122000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	16000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	13000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18923000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16235000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.41	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.41	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2008Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5500000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	37200000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	21600000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	70000	USD
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26691	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1848000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	179000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	161000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	5068000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3100000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	480000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	29000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	71000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	900000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1075000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	914000	USD

Files In Submission

Name	View Source	Status
0001144204-15-059224-index-headers.html	Edgar Link	pending
0001144204-15-059224-index.html	Edgar Link	pending
0001144204-15-059224.txt	Edgar Link	pending
0001144204-15-059224-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20150630.xml	Edgar Link	completed
ibio-20150630.xsd	Edgar Link	pending
ibio-20150630_cal.xml	Edgar Link	unprocessable
ibio-20150630_def.xml	Edgar Link	unprocessable
ibio-20150630_lab.xml	Edgar Link	unprocessable
ibio-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg10.jpg	Edgar Link	pending
v420530_10k.htm	Edgar Link	pending
v420530_ex23-1.htm	Edgar Link	pending
v420530_ex31-1.htm	Edgar Link	pending
v420530_ex31-2.htm	Edgar Link	pending
v420530_ex32-1.htm	Edgar Link	pending
v420530_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2015 Q2 Form 10-K Financial Statement

#000114420415059224 Filed on October 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2015 Q2 Form 10-K Financial Statement

#000114420415059224 Filed on October 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio